Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Comparing ETFs and mutual funds for retirement reveals tax efficiency differences driven by turnover, distributions, and account placement.
28,114 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Playnance confirms G Coin launch ahead of its March 18 Token Generation Event, underscoring a live ecosystem with hun...
DocuSign's 2026 earnings narrative centers on ARR expansion, margin discipline, and stronger cash flow in a competiti...
Developers shift from splashy amenities to intentional spaces that foster belonging, a move that also redefines how l...
Remitly’s 2026 earnings outlook hinges on user growth, cross-border volumes, and unit economics. This guide breaks do...
Greg Abel is quietly rebalancing Berkshire Hathaway’s equity book, moving away from U.S. financials and toward intern...
XRP surged to a two-month peak, while on-chain activity jumped, signaling renewed investor interest. Analysts say the...
As Ethereum’s core stewardship rethinks its mission, Vitalik Buterin advocates a leaner, more opinionated foundation....
Solana has edged ahead of Ethereum in weekly DEX volume for April 2026, yet Ethereum retains a dominant DeFi TVL. XRP...
SpaceX is pursuing a landmark IPO with a $1.75 trillion target, a level that demands extraordinary growth. Experts ou...
Abridge secures NVIDIA and Eli Lilly support to push an ambient AI platform toward a full hospital operating system. ...
A high-stakes moment for semiconductor supply and AI chip strategy has investors watching ASML. This analysis explain...